Trial report in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06348576 (A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
TypeinterventionalSponsorAddpharma Inc.Ran2024 to 2025Enrolled280ConditionsHypertension,EssentialArmsAD-209, AD-2091, AD-209 Placebo, AD-2091 Placebo
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Jeong Cheon AhnDepartment of Cardiology, Korea University Ansan Hospital (J.C.A.).ORCID 0000-0003-1535-5480
Cheol Whan LeeDivision of Cardiology, Asan Medical Center, Seoul, Republic of Korea (C.W.L.).ORCID 0000-0003-3987-2159
Jong-Hwa AhnDivision of Cardiology, Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea (J.-H.A.).ORCID 0000-0002-5446-0446
Kyung Hee LimDivision of Cardiology, Dong-A University Hospital, Busan, Republic of Korea (K.H.L.).
Il Suk SohnDepartment of Cardiology, Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea (I.S.S.).ORCID 0000-0001-8004-5185
Ki-Chul SungDivision of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea (K.-C.S.).ORCID 0000-0001-5630-2145
Kye Hun KimDepartment of Cardiovascular Medicine, Chonnam National University Medical School/Hospital, Gwangju, Republic of Korea (K.H.K.).ORCID 0000-0002-6885-1501
Jang-Ho BaeDivision of Cardiology, Konyang University Hospital, Daejeon, Republic of Korea (J.-H.B.).ORCID 0000-0001-9533-7527
Seung Pyo HongDepartment of Cardiology, Daegu Catholic University Medical Center, Republic of Korea (S.P.H.).ORCID 0000-0002-0028-9647
Won-Young JangDepartment of Cardiology, Daegu Catholic University Medical Center, Republic of Korea (S.P.H.).ORCID 0000-0003-1244-5691
Sang-Ho JoDivision of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea (S.-H.J.).ORCID 0000-0002-2063-1542
Seung Hwan HanDivision of Cardiology, Gachon University Gil Hospital, Incheon, Republic of Korea (S.H.H.).ORCID 0000-0002-7315-7557
Ji Bak KimDepartment of Cardiology, Hanil General Hospital, Seoul, Republic of Korea (J.B.K.).
Chan Joo LeeDivision of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea (C.J.L.).ORCID 0000-0002-8756-409X
Ju-Hee LeeDivision of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea (J.-H.L.).
Namkyun KimDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea (N.K.).ORCID 0000-0001-8457-0403
Eun Joo ChoDivision of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital (E.J.C.), The Catholic University of Korea, Seoul.ORCID 0000-0002-1695-9852
Jung-Hoon SungDivision of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea (J.-H.S.).ORCID 0000-0003-3515-5283
Hyo-Suk AhnDivision of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine (H.-S.A.), The Catholic University of Korea, Seoul.ORCID 0000-0001-9531-7286
Seok-Yeon KimDepartment of Cardiology, Seoul Medical Center, Republic of Korea (S.-Y.K.).
Jinho ShinDivision of Cardiology, Department of Internal Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea (J.S.).ORCID 0000-0001-6706-6504
Suk Min SeoDivision of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital (S.M.S.), The Catholic University of Korea, Seoul.ORCID 0000-0003-2424-5275
Soon Jun HongDepartment of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul (S.J.H.).ORCID 0000-0003-4832-6678
Weon KimDivision of Cardiovascular, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Republic of Korea (W.K.).ORCID 0000-0003-1264-9870
Chang-Gyu ParkDivision of Cardiology, Korea University Guro Hospital, Seoul (C.-G.P.).ORCID 0000-0001-9654-9257
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundAlthough low-dose triple single-pill combination therapies show promising efficacy and safety, studies comparing them to standard-dose monotherapies remain limited. This phase III, randomized, double-blind trial evaluated the efficacy and safety of a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone versus standard-dose telmisartan monotherapy in patients with essential hypertension.
methodsAfter a 4-week placebo run-in period, 314 eligible subjects were randomized to either receive telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg or telmisartan 40 mg for 8 weeks. The primary efficacy end point was the change in mean sitting systolic blood pressure from baseline to week 8, with noninferiority assessed in the per-protocol set (PPS), followed by superiority testing in the full analysis set using a gatekeeping approach to control for type I error.
resultsAt week 8, the combination group demonstrated significant mean sitting systolic blood pressure reduction compared with monotherapy in the per-protocol set analysis (least squares mean difference, -3.8 mm Hg [95% CI: -6.7 to -0.9];
conclusionsLow-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06348576.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.